EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety assessment of frunevetmab for osteoarthritis pain in cats: disproportionality analysis of the Food and Drug Administration Animal Drug Adverse Events database

Sicherheitsbewertung von Frunevetmab bei Schmerzen durch Osteoarthritis bei Katzen: Disproportionalitätsanalyse der FDA Animal Drug Adverse Events-Datenbank

Xiaoheng Lai iD, Li Lin iD, Yan Chen iD, Lifang Wu iD, Yaping Huang, Maohua Chen iD

Journal of Veterinary Internal Medicine · 21.01.2026 · 40 (1)

DOI: 10.1093/jvimsj/aalag003 ↗

Auf einen Blick

In 5.248 Frunevetmab-Berichten aus der FDA-ADAE-Datenbank wurden 19 signifikante Preferred Terms gefunden. Häufig waren Juckreiz, Hautstörungen und Alopezie; neue Signale betrafen u. a. Hautulzeration und Injektionsschmerz.

Fragestellung

Welche unerwünschten Ereignisse sind in Real-World-Daten bei Katzen unter Frunevetmab mit disproportionalen Signalen verbunden?

Methode

Disproportionalitätsanalyse von Berichten für Katzen mit Frunevetmab aus der FDA ADAE-Datenbank; Daten von Januar 2022 bis Dezember 2024; Auswertung mit ROR, PRR, Bayesian confidence-propagation neural network und MGPS.

Ergebnisse

Aus 33.378 feline AE-Berichten wurden 5.248 frunevetmab-spezifische Berichte analysiert. Betroffen waren 24 Systemorgankategorien. 19 signifikante PTs wurden identifiziert; die stärksten Signale betrafen Hautulzeration, unspezifische Hautstörungen, unspezifische Hautläsionen, Injektionsschmerz und Dermatitis/Ekzem.

Einschränkungen

Disproportionalitätsanalyse; die Befunde sind hypothesengenerierend und müssen validiert werden.

Schlussfolgerung der Autor:innen

Die Autor:innen identifizierten neue potenzielle AE-Signale für Frunevetmab und betonten die Notwendigkeit einer engmaschigen klinischen Überwachung.

Kernaussagen

  • 5.248 frunevetmab-spezifische Berichte wurden ausgewertet
  • 19 signifikante PTs in 24 Systemorgankategorien
  • Neue Signale u. a. für Hautulzeration und Injektionsschmerz

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 11.02.2026. Verfasst von Xiaoheng Lai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Second Affiliated Hospital of Xiamen Medical College, No. 566 Shengguang Street, Xiamen, Fujian 361024, China. Hauptthemen laut MEDLINE: Cat Diseases, Osteoarthritis, Pain, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Frunevetmab is a felinized anti-nerve growth factor monoclonal antibody that alleviates osteoarthritis (OA) pain in cats by blocking nerve growth factor (NGF) signaling. While its efficacy is established, comprehensive real-world safety profiles remain limited. Hypothesis/Objectives To analyze frunevetmab-associated adverse events (AEs) using real-world data from the United States Food and Drug Administration (FDA) Animal Drug Adverse Events (ADAE) database. Animals Adverse event reports submitted for cats receiving frunevetmab, extracted from the FDA ADAE database (January 2022 - December 2024).

Methods

Disproportionality in frunevetmab-associated AEs was assessed by calculating the reporting odds ratio, the proportional reporting ratio, the Bayesian confidence-propagation neural network, and the multi-item gamma Poisson shrinker.

Results

From 33,378 feline AE reports, 5,248 frunevetmab-specific reports were analyzed. Frunevetmab-induced AEs spanned 24 system organ categories. Among the 19 significant preferred terms (PTs) identified, the most frequently reported AEs included pruritus, unspecified skin disorders, alopecia, dermatitis and eczema, and unspecified skin lesions. Notably, the AEs with the highest signal strength were skin ulceration, unspecified skin disorders, unspecified skin lesions, injection site pain, and dermatitis and eczema. In addition, unexpected significant AEs (e.g., abnormal cytology, arthritis, paresis) were detected, all of which were absent from the package insert. Conclusions and clinical importance We identified new potential AE signals for frunevetmab, emphasizing the need for robust clinical monitoring. Although these hypothesis-generating findings from disproportionality analysis require validation, they offer immediate, valuable guidance for veterinarians to optimize the safe use of this treatment in cats with OA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cat DiseasesOsteoarthritisPainAntibodies, MonoclonalAnimalsCatsUnited StatesUnited States Food and Drug AdministrationDatabases, FactualAdverse Drug Reaction Reporting Systems

Stichwörter der Autor:innen

ADAEFrunevetmabadverse eventpharmacovigilance

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Pharmacy, Second Affiliated Hospital of Xiamen Medical College, No. 566 Shengguang Street, Xiamen, Fujian 361024, China.
  • Department of Medical Oncology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, No. 134 Dongjie Street, Fuzhou 350001, Fujian,…
  • Department of Pharmacy, Pingtan Comprehensive Experimental Area Hospital, Pingtan Comprehensive Experimental Area, Fuzhou, Fujian 350400, PR China.
  • Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, No. 134 Dongjie Street, Fuzhou, Fujian 350001, PR Chin…

ORCID-Profile: Xiaoheng Lai, Li Lin, Yan Chen, Lifang Wu, Maohua Chen

Zitieren

APA

Lai, X., Lin, L., Chen, Y., Wu, L., Huang, Y., & Chen, M. (2026). Safety assessment of frunevetmab for osteoarthritis pain in cats: disproportionality analysis of the Food and Drug Administration Animal Drug Adverse Events database. Journal of Veterinary Internal Medicine, 40(1). https://doi.org/10.1093/jvimsj/aalag003

Vancouver

Lai X, Lin L, Chen Y, Wu L, Huang Y, Chen M. Safety assessment of frunevetmab for osteoarthritis pain in cats: disproportionality analysis of the Food and Drug Administration Animal Drug Adverse Events database. Journal of Veterinary Internal Medicine. 2026;40(1). doi:10.1093/jvimsj/aalag003

BibTeX
@article{Lai2026,
  author = {Lai, Xiaoheng and Lin, Li and Chen, Yan and Wu, Lifang and Huang, Yaping and Chen, Maohua},
  title = {Safety assessment of frunevetmab for osteoarthritis pain in cats: disproportionality analysis of the Food and Drug Administration Animal Drug Adverse Events database},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2026},
  volume = {40},
  number = {1},
  doi = {10.1093/jvimsj/aalag003}
}
Kostenlos starten →